---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-25-000098"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T20:59:55.659340+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Neurogene Reports Positive Interim Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome

## Summary
- All 8 pediatric participants (ages 4-10) showed functional gains across spectrum of disease severity.
- 35 developmental milestones/skills acquired across hand function, language/communication, and gross motor domains.
- NGN-401 at the 1E15 vg dose was generally well-tolerated with no evidence of HLH in any participant.
- Gains were durable with continued skill acquisition observed up to 24 months post treatment.
- Company to discuss results at Stifel 2025 Healthcare Conference webcast on November 12, 2025.

## SEC filing metadata
- accession: 0001404644-25-000098
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464425000098/0001404644-25-000098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464425000098/ngne-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-25-000098
- JSON: https://secwatch.observer/filing/0001404644-25-000098.json
- Plain text: https://secwatch.observer/filing/0001404644-25-000098.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.